PLT Test Blog

As the symptoms get stronger, so does the therapy,  going up in steps from May to July/August and then down to Octobe r Today’s post is a practical one.   There is an interesting scientific one in preparation all about applying the emerging science of gene silencers and enhancers.   I discovered in previous years that the summertime raging exhibited by Monty, now aged 12 with ASD, could be prevented using a small dose of the L-type calcium channel blocker, Verapamil .  Verapamil is also a mast cell stabilizer and blocks potassium channels linked to some inflammatory response. This summer the story has repeated itself.  As the amount of airborne allergens increases from spring to summer the same seemingly mild allergy symptoms return.  So in late spring there was some sneezing and by mid-summer some eczema (atopic dermatitis) behind the knees and finally a very mild amount of asthma (slight wheezing); all of which were easily treated. This apparently mild a...

Antonio Hardan, the psychiatrist at the Stanford School of Medicine, has published another paper.   Hardan is interesting, he is a clinician rather than a rocket scientist, but he gets involved in a very wide variety of clinical trials, usually of existing drugs that might be effective in autism. In his latest paper, this time about Glutamatergic Dysfunction in Autism, he highlights the problems with clinical trials:- ·         Heterogeneity of autism ·         Subjective rating scales rather than biological measures. In other words there is no single autism and there is no good way to reliably measure the efficacy of any drug tested on it.  Consider what that really means . Developing Medications Targeting Glutamatergic Dysfunction in Autism: Progress to Date     Hardan  really should know about this, just look at the clinical trials he has been involved in:- So why bother with Clinical Trial...